Sustaining pneumococcal vaccination after transitioning from Gavi support: A modelling and cost-effectiveness study in Kenya

The Lancet Global Health Apr 19, 2019

Ojal J, et al. - In this modelling and cost-effectiveness study, researchers estimated the cost-effectiveness of continuing pneumococcal conjugate vaccine (PCV) using Gavi's schedule of vaccine prices, reaching a peak of $3.05 per dose in 2027, when Kenya becomes fully self-financing. To sustain its health gains, continued use of PCV is essential. Based on the $1,445 per capita Kenyan gross domestic product—and compared with other vaccines—continued use of PCV at full cost is cost-effective (based on the assumption that any reduction in disease will result in a reduction in mortality). While affordability is likely to be a concern, findings supported vaccine budget expansion in Kenya. The investigators predicted that $153 in 2032 would be the incremental cost per disability-adjusted life-year averted from continuing PCV.

Full text available Go to Original

Sign-up to continue reading. It is free & takes less than 2 mins

  • 45 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Free & unlimited access to original articles and quizzes
  • Nonloggedinlock icon
    Secure: we never sell your data
This article is only available to members. Are you a doctor? Click here to signup for free.
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay